Benitec Biopharma Inc (BNTC) - News Archive

Benitec Biopharma Inc. Announces $30 Million Common Stock OfferingOn March 25, 2025, Benitec Biopharma Inc. (Nasdaq: BNTC) announced a significant move in its financing strategy, revealing the pricing of a combined $30...

Positive Clinical Outcomes for Benitec Biopharma’s BB-301 in Phase 1b/2a Study Amidst Market Performance Struggles Benitec Biopharma Inc. has recently reported promising results from its Phase 1b/2a clinical study of BB...

: Gene therapy has emerged as a promising frontier in the treatment of genetic disorders, with innovative approaches such as RNA interference gaining traction. This article discusses the latest developments from Benitec...

: Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, inherited disorder that predominantly affects the muscles involved in swallowing. Benitec Biopharma, a renowned biotechnology company, has reported promising result...

Australian-based Benitec Biopharma made a significant announcement indicating positive interim results from their ongoing Phase 1b/2a clinical trial for BB-301. In revolutionary strides, this gene therapy under developm...

Rejuvenated Investor Confidence Fuels Benitec Biopharma s Successful $40 Million Private Placement Financing HAYWARD, Calif., April 18, 2024 – Benitec Biopharma Inc. (NASDAQ: BNTC), a clinical-stage biotechnology compan...

Benitec Biopharma, a leading biotechnology company, recently announced the initiation of the first clinical trial for their gene therapy candidate, BB-301. This breakthrough marks a significant milestone in the field of...